- Home
- PASG vs INTS Comparison
PASG vs INTS Comparison
Compare PASG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- INTS
- Stock Information
- Founded
- PASG 2017
- INTS 2012
- Country
- PASG United States
- INTS United States
- Employees
- PASG N/A
- INTS N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- INTS Health Care
- Exchange
- PASG Nasdaq
- INTS Nasdaq
- Market Cap
- PASG 31.1M
- INTS 30.8M
- IPO Year
- PASG 2020
- INTS 2023
- Fundamental
- Price
- PASG $0.37
- INTS $0.54
- Analyst Decision
- PASG Strong Buy
- INTS Strong Buy
- Analyst Count
- PASG 3
- INTS 3
- Target Price
- PASG $7.67
- INTS $8.50
- AVG Volume (30 Days)
- PASG 193.4K
- INTS 354.7K
- Earning Date
- PASG 05-20-2025
- INTS 05-20-2025
- Dividend Yield
- PASG N/A
- INTS N/A
- EPS Growth
- PASG N/A
- INTS N/A
- EPS
- PASG N/A
- INTS N/A
- Revenue
- PASG N/A
- INTS N/A
- Revenue This Year
- PASG N/A
- INTS N/A
- Revenue Next Year
- PASG N/A
- INTS N/A
- P/E Ratio
- PASG N/A
- INTS N/A
- Revenue Growth
- PASG N/A
- INTS N/A
- 52 Week Low
- PASG $0.30
- INTS $0.50
- 52 Week High
- PASG $1.64
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- PASG 46.97
- INTS 18.34
- Support Level
- PASG $0.33
- INTS $0.55
- Resistance Level
- PASG $0.42
- INTS $0.59
- Average True Range (ATR)
- PASG 0.04
- INTS 0.12
- MACD
- PASG 0.01
- INTS -0.02
- Stochastic Oscillator
- PASG 33.27
- INTS 4.71
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.